Notice to unitholders/shareholders of UCITS (the Fund(s))

We would like to inform you that SEB Asset Management S.A. (SEB AM), acting as management company, will merge with SEB Investment Management AB (SEB IM AB) as of 2 November 2016. In connection with this, SEB IM AB will also open a branch office in Luxembourg. The merger and branch will simplify the governance structure of the funds’ management companies in SEB Group.

SEB IM AB was established 19 May 1978 as a limited liability company (aktiebolag, AB). Its registered office in Sweden is located at
Sveavägen 8, SE-106 40 Stockholm. Sweden’s financial supervisory authority, Finansinspektionen, has authorised SEB IM AB to manage UCITS and for the discretionary management of financial instruments and investment portfolios under the Swedish UCITS Act (SFS 2004:46).

How you and the Funds are affected

• The Funds are currently managed by SEB AM.  After the merger of SEB AM and SEB IM AB, the Funds will be managed directly by SEB IM AB or via its Luxembourg branch. The Funds continue to be domiciled in Luxembourg. Risk management and central ad-ministration activities will be conducted by SEB IM AB, the Luxembourg branch.
• The Funds’ investments will comply with ethical and/or sustainability principles, as followed by SEB IM AB.
• G20, Singapore and Hong Kong will be added to the list of countries that issue or guarantee transferable securities and money market instruments in which the Funds may invest.
• An amendment in Section 5.2.1 “Restriction on issue” of the Funds’ prospectus allows the Funds’ management company to take appropriate action in regard to prohibited persons as they are defined by the Fund’s prospectus. For example, an appropriate action could include blocking the account of a prohibited person. This would be done in accordance with laws and regulations, and in the best interest of the Funds and their investors.
• The Funds may apply a 10% threshold for redemptions and may defer redemptions that exceed this threshold. In practical terms, this means that if the total redemption orders from all investors exceed 10% of a sub fund's net asset value (NAV) on the same day, the Funds can reduce the size of the redemption orders so the total does not exceed 10% of the NAV. To increase transparency, brokerage fees will be broken down into broker execution fees and research fees. Research fees, if applicable, may reach a maxi-mum total of 0.20% annually of the net assets of the relevant sub fund.
• The updated prospectus for the relevant Funds will include changes made to reflect regulatory requirements as well as clarifications and editorial changes.
• Updated product documentation is available free of charge at the registered office of SEB AM and at the registered office of each SICAV UCITS.
• If you do not wish to continue investing in your Fund, you may redeem your units/shares. In order to do this without being charged a redemption fee, you must redeem within 1 month of the date of this notice.  Note that redemption may result in tax consequenc-es.

Kindly contact us with any questions regarding the information described here by e-mail AM@sebgroup.lu.

List of UCITS

• SEB Concept Biotechnology
• SEB deLuxe
• SEB Fund 1
• SEB Fund 2
• SEB Fund 3
• SEB Fund 4
• SEB Fund 5
• SEB High Yield
• SEB SICAV 1
• SEB SICAV 2
• SEB Strategy Fund

Changes regarding SEB Concept Biotechnology Fund

As of the implementation date mentioned in this document, SEB Concept Biotechnology may use swing pricing. Swing pricing is designed to protect the Unitholders’ investments in a situation where substantial sums flow in or out of the Funds. If this occurs, the Management Company may have to make adjustments, such as trading on the market, in order to maintain the desired asset allo-cation for the Funds. Trading can incur costs that affect the unit price of the Funds and the value of existing unitholders.